LENT Prognostic Score for Malignant Pleural Effusion
Predicts survival in patients with malignant pleural effusion (MPE). Scores LDH, ECOG status, NLR, and tumour type (LENT) to guide management decisions.
Score interpretation
LENT score 0–1 — median survival >1 year
→ Aggressive management appropriate; tunnelled pleural catheter (TPC) or pleurodesis; systemic treatment ongoing
LENT score 2–4 — median survival ~3–6 months
→ Balance symptomatic management with quality of life; TPC preferred to serial thoracocentesis; palliative care input
LENT score 5–7 — median survival <3 months
→ Focus on symptom relief and quality of life; single therapeutic thoracocentesis; palliative care; avoid invasive procedures
Interpretation bands for the LENT Score. Apply clinical judgement and local guidance.
References
- Clive AO et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax. 2014;69(12):1098–1104.
Related
Curated clinical cross-links plus same-class fallbacks.
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Acetazolamide (Ménière's Disease) · Carbonic Anhydrase Inhibitor (Diuretic)
- Zinc acetate · Zinc salt (Wilson's disease)
- Sulfasalazine · Aminosalicylate / Disease-Modifying Antirheumatic Drug (DMARD)
- Hydroxycarbamide (Hydroxyurea) · Cytoreductive agent / Sickle cell disease / CML
- Hydroxycarbamide (Hydroxyurea) · Cytotoxic / Disease-Modifying Agent
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.